Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research ; volume:7 ; number:1 ; day:4 ; month:9 ; year:2024 ; pages:1-6 ; date:12.2024
npj digital medicine ; 7, Heft 1 (4.9.2024), 1-6, 12.2024
- Urheber
-
Erdemli, Gül
Grammatikopoulou, Margarita
Wagner, Bertil
Vairavan, Srinivasan
Curcic, Jelena
Aarsland, Dag
Wittenberg, Gayle
Nikolopoulos, Spiros
Muurling, Marijn
Fröhlich, Holger
Boer, Casper de
Shanbhag, Niraj M.
Nies, Vera J. M.
Coello, Neva
Gove, Dianne
Diaz, Ana
Foy, Suzanne
Dartee, Wim
Brem, Anna-Katharine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41746-024-01211-8
- URN
-
urn:nbn:de:101:1-2411202140100.903664591245
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Erdemli, Gül
- Grammatikopoulou, Margarita
- Wagner, Bertil
- Vairavan, Srinivasan
- Curcic, Jelena
- Aarsland, Dag
- Wittenberg, Gayle
- Nikolopoulos, Spiros
- Muurling, Marijn
- Fröhlich, Holger
- Boer, Casper de
- Shanbhag, Niraj M.
- Nies, Vera J. M.
- Coello, Neva
- Gove, Dianne
- Diaz, Ana
- Foy, Suzanne
- Dartee, Wim
- Brem, Anna-Katharine
- SpringerLink (Online service)
Ähnliche Objekte (12)
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study
Practical considerations for choosing a mouse model of Alzheimer’s disease
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
Surface analysis for Alzheimer’s
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Intranasal Insulin for Alzheimer’s Disease
Photoaffinity Probes for Alzheimer’s Disease
Blood biomarkers for Alzheimer’s disease
Neuroimaging Biomarkers for Alzheimer’s Disease
Active immunotherapy options for Alzheimer’s disease
Urinary metabolic phenotyping for Alzheimer’s disease
Probing neural circuit mechanisms in Alzheimer’s disease using novel technologies
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study
Practical considerations for choosing a mouse model of Alzheimer’s disease
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
Surface analysis for Alzheimer’s
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Intranasal Insulin for Alzheimer’s Disease
Photoaffinity Probes for Alzheimer’s Disease
Blood biomarkers for Alzheimer’s disease
Neuroimaging Biomarkers for Alzheimer’s Disease
Active immunotherapy options for Alzheimer’s disease
Urinary metabolic phenotyping for Alzheimer’s disease
Probing neural circuit mechanisms in Alzheimer’s disease using novel technologies
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study
Practical considerations for choosing a mouse model of Alzheimer’s disease
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
Surface analysis for Alzheimer’s
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Intranasal Insulin for Alzheimer’s Disease
Photoaffinity Probes for Alzheimer’s Disease
Blood biomarkers for Alzheimer’s disease
Neuroimaging Biomarkers for Alzheimer’s Disease
Active immunotherapy options for Alzheimer’s disease
Urinary metabolic phenotyping for Alzheimer’s disease